721 related articles for article (PubMed ID: 35838667)
1. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK
JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667
[TBL] [Abstract][Full Text] [Related]
2. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
3. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
4. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
Kenigsberg TA; Goddard K; Hanson KE; Lewis N; Klein N; Irving SA; Naleway AL; Crane B; Kauffman TL; Xu S; Daley MF; Hurley LP; Kaiser R; Jackson LA; Jazwa A; Weintraub ES
Vaccine; 2023 Sep; 41(39):5678-5682. PubMed ID: 37599140
[TBL] [Abstract][Full Text] [Related]
6. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
Rosenblum HG; Gee J; Liu R; Marquez PL; Zhang B; Strid P; Abara WE; McNeil MM; Myers TR; Hause AM; Su JR; Markowitz LE; Shimabukuro TT; Shay DK
Lancet Infect Dis; 2022 Jun; 22(6):802-812. PubMed ID: 35271805
[TBL] [Abstract][Full Text] [Related]
7. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
[TBL] [Abstract][Full Text] [Related]
8. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines.
Gonen T; Barda N; Asraf K; Joseph G; Weiss-Ottolenghi Y; Doolman R; Kreiss Y; Lustig Y; Regev-Yochay G
JAMA Netw Open; 2023 Sep; 6(9):e2332813. PubMed ID: 37682571
[TBL] [Abstract][Full Text] [Related]
10. Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
Lu Y; Matuska K; Nadimpalli G; Ma Y; Duma N; Zhang HT; Chiang Y; Lyu H; Chillarige Y; Kelman JA; Forshee RA; Anderson SA
JAMA; 2024 Mar; 331(11):938-950. PubMed ID: 38502075
[TBL] [Abstract][Full Text] [Related]
11. Sex and gender differences in adverse events following influenza and COVID-19 vaccination.
Yin A; Wang N; Shea PJ; Rosser EN; Kuo H; Shapiro JR; Fenstermacher KZJ; Pekosz A; Rothman RE; Klein SL; Morgan R
Biol Sex Differ; 2024 Jun; 15(1):50. PubMed ID: 38890702
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
[TBL] [Abstract][Full Text] [Related]
13. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
Moscara L; Venerito V; Martinelli A; Di Lorenzo A; Toro F; Violante F; Tafuri S; Stefanizzi P
Vaccine; 2023 Aug; 41(38):5655-5661. PubMed ID: 37544827
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
15. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
[TBL] [Abstract][Full Text] [Related]
19. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.
Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835
[TBL] [Abstract][Full Text] [Related]
20. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
